CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of Telaprevir in patients with hepatitis C genotype 1 infection: The German Telaprevir early access program
DOI 10.1055/s-0033-1360892
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Wedemeyer, S Mauss, HW Busch, A Umgelter, P Buggisch, H Klinker, D Hüppe, A Hill, I Lonjon-Domanec, S Zeuzem
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and aims: Anaemia is a common adverse event during treatment for HCV infection. HEP3002 is an ongoing, open-label, early access program of telaprevir in 16 countries, for patients with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis. This analysis is of the data from the 95 German patients, evaluated for 16 weeks of treatment. Methods: Liver biopsy or non-invasive tests showing severe…
Zitieren
Zitierempfehlung
H Wedemeyer, S Mauss, HW Busch, A Umgelter, P Buggisch, H Klinker, D Hüppe, A Hill, I Lonjon-Domanec, S Zeuzem (2014) Efficacy and safety of Telaprevir in patients with hepatitis C genotype 1 infection: The German Telaprevir early access program. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0033-1360892
Mit CareLit weiterarbeiten